Appreciate your optimism, Lucretious, and I agree that the sector Echo IQ is targeting has massive potential. But potential doesn't pay the bills,
execution does.I’m not against publicity per se, but there’s a big difference between strategic comms to support sales and paying for stock-promoting research to drive the share price ahead of a likely capital raise. That’s where the concern lies: short-term optics over long-term fundamentals.The March quarterly does reference positive steps, but let’s not confuse interest with revenue. Where are the contracts? Where are the first-mover hospitals actually paying to use the product?If the product truly offers measurable clinical and financial value, as claimed, it shouldn't need “spruiking” to entice uptake. The incentive to adopt would be built-in. The fact we’re still relying on promotional campaigns instead of referenceable customers says a lot.Re: Top 20 holders selling—possibly. But that's even more reason for management to focus on building real commercial traction. A capital raise done at a higher price only helps if it’s justified by fundamentals. Otherwise, it just kicks the can further down the road.I want this company to succeed. But trust is built on results, not just anticipation or hype.
Management should be focused on building the business—not spruiking the stock. If you pay peanuts, you get monkey-like behaviour, and that’s exactly what we’re seeing: a CEO more focused on pumping the share price than delivering genuine commercial outcomes. Worse still, it’s being done with shareholder funds!.
The “peanuts” I’m referring to are stock options tied to share price performance rather than actual business results—a flawed incentive structure that rewards hype over execution and encourages short-term, performative behaviour.
.
(20min delay)